Xevinapant combined with pembrolizumab in patients with advanced, pretreated colorectal and pancreatic cancer: results of the phase 1b/2 CATRIPCA trial.
Allison VoisinCatherine TerretCamille SchifflerAnne-Sophie BidauxHelene VanackerMarlène Perrin-NiquetMaud BarberyArmelle VinceneuxLauriane EberstPierre StéphanGwenaele GarinDany SpaggiariDavid PérolYenkel Grinberg-BleyerPhilippe Alexandre CassierPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Xevinapant combined with pembrolizumab was well tolerated with no unexpected adverse events. However, anti-tumor activity was low.